iCAD Announces Q3 2024 Financial Results Release and Participation in Craig-Hallum Conference

iCAD Prepares for Q3 2024 Financial Disclosure

iCAD, Inc. (NASDAQ: ICAD), a global leader in AI-powered cancer detection solutions, has announced its plans to release financial results for the third quarter ended September 30, 2024. The company will host a conference call on Wednesday, November 13, 2024, at 4:30 PM Eastern Time, following the market close 1

1

Participation in Craig-Hallum Alpha Select Conference

In a separate announcement, iCAD revealed that its top executives, CEO Dana Brown and CFO Eric Lonnqvist, will be attending the 15th Annual Craig-Hallum Alpha Select Conference. The event is scheduled for Tuesday, November 19, 2024, at the Sheraton New York Times Square Hotel 2

2

iCAD's AI-Powered Healthcare Solutions

iCAD specializes in clinically proven AI-powered cancer detection solutions, with a particular focus on breast health. The company's flagship product, the ProFound Breast Health Suite, provides AI-powered mammography analysis for breast cancer detection, density assessment, and risk evaluation 1

1

2

Key highlights of iCAD's market presence include:

• Availability in over 50 countries
• Utilization by thousands of providers serving millions of patients
• An estimated 40 million mammograms processed worldwide in the last five years
• Nearly 30% of processed mammograms being tomosynthesis 1

  1

  2

  2

Related Stories

iCAD to Present at iAccess Alpha Buyside Best Ideas Fall Conference 2024

iCAD Showcases Advanced AI Solutions for Breast Cancer Detection at SABCS and RSNA 2024

iCAD and Cascaid Health Partner to Revolutionize Breast Cancer Detection with AI-Powered Solutions

Q2 2024 Financial Results: A Mixed Bag for Tech and Healthcare Companies

Future Outlook and Potential Challenges

While iCAD expresses optimism about its AI-powered solutions, the company acknowledges potential challenges and uncertainties. These include:

• The impact of supply and manufacturing constraints
• Uncertainty of future sales levels
• Potential litigation matters
• Protection of patents and proprietary rights
• Possible technological obsolescence
• Increased competition
• Changes in Medicare or other reimbursement policies 1

  1

  2

  2

Investor Relations and Market Position

iCAD's participation in the Craig-Hallum Alpha Select Conference underscores its position as a notable player in the healthcare technology sector. The conference, which features companies with sub-$500 million market caps, attractive business models, and above-average growth prospects, provides iCAD with an opportunity to showcase its AI-driven innovations to institutional investors 2

2